News Column

Researchers at National Cancer Institute Target DNA Vaccines (HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest...

June 30, 2014



Researchers at National Cancer Institute Target DNA Vaccines (HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques)

By a News Reporter-Staff News Editor at AIDS Vaccine Week -- Investigators publish new report on Biotechnology. According to news reporting out of Frederick, Maryland, by NewsRx editors, research stated, "Vaccination with HIV/SIV DNAs elicits potent T-cell responses. To improve humoral immune responses, we combined DNA and protein in a co-immunization protocol using in vivo electroporation in mice and macaques."

Our news journalists obtained a quote from the research from National Cancer Institute, "DNA&protein co-immunization induced higher antibody responses than DNA or protein alone, or DNA prime/protein boost in mice. DNA&protein co-immunization induced similar levels of cellular responses as those obtained by DNA only vaccination. The inclusion of SIV or HIV Env gp120 protein did not impair the development of cellular immune responses elicited by DNA present in the vaccine regimen. In macaques, the DNA&protein co-immunization regimen also elicited higher levels of humoral responses with broader cross-neutralizing activity. Despite the improved immunogenicity of DNA&protein co-immunization, the protein formulation with the EM-005 (GLA-SE) adjuvant further increased the anti-Env humoral responses. Dissecting the contribution of EM-005, we found that its administration upregulated the expression of co-stimulatory molecules and stimulated cytokine production, especially IL-6, by dendritic cells in vivo. These terminally differentiated, mature, dendritic cells possibly promote higher levels of humoral responses, supporting the inclusion of the EM-005 adjuvant with the vaccine."

According to the news editors, the research concluded: "Thus, DNA&protein co-immunization is a promising strategy to improve the rapidity of development, magnitude and potency of the humoral immune responses."

For more information on this research see: HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine, 2013;31(36):3747-55. (Elsevier - www.elsevier.com; Vaccine - www.journals.elsevier.com/vaccine)

Our news journalists report that additional information may be obtained by contacting J. Li, Human Retrovirus Section, Vaccine Branch, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, United States. Additional authors for this research include A. Valentin, V. Kulkarni, M. Rosati, R.K. Beach, C. Alicea, D. Hannaman, S.G. Reed, B.K. Felber and G.N Pavlakis (see also Biotechnology).

Keywords for this news article include: Biotechnology, Maryland, HIV/AIDS, Virology, Frederick, RNA Viruses, Vaccination, DNA Research, DNA Vaccines, Immunization, Retroviridae, United States, HIV Infections, Medical Devices, Synthetic Vaccines, Vertebrate Viruses, Biological Products, Primate Lentiviruses, North and Central America.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: AIDS Vaccine Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters